Fig. 1

Establishment and characterization of sarconoids derived from angiosarcoma patients. (a) Schematic illustration of the workflow for the generation of sarconoids. (b) Histopathological staining of vascular neoplasm markers (CD31, CD157, ERG, and p53) and a lymphatic marker (D2-40) in primary resected angiosarcoma tumors and their corresponding sarconoids; scale bars, 50 μm. (c) Heat map of the scaled FPKM values of representative gene sets significantly upregulated in the patient-derived sarconoids and tumor tissue. (d) Gene set variation analysis (GSVA)-based subtyping of normal tissue, patient #2 tumor tissue, and patient #2-, #4 and #9-sarconoids against published gene sets (GeneRIF Biological Term Annotations), among the sarcoma subtypes. (e) Dot plot of the mean expression of canonical marker genes using the CellMarker database for 14 major lineages from each patient #2-sarconoid cluster, as indicated. (f) Quantification of PROCR expression by qRT-PCR in normal and cancer tissues (n = 3). An unpaired t-test was used; *p < 0.05, **p < 0.01,***p < 0.001,****p < 0.0001. (g) IHC assays of serial sections from patient #2- and patient #4-sarconoids for PROCR expression. Scale bars, 100 μm